Serum samples should not be used to assess circulating matrix metalloproteinase-9 levels as a prognostic marker of disease [4]

International Journal of Cancer

Volumn 118, Issue 3, 2006, Pages 789-

  Tanus Santos, Jose E ^a   Gerlach, Raquel F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; GELATINASE B;

BLOOD SAMPLING; CANCER PATIENT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HEAD AND NECK CARCINOMA; HUMAN; LABORATORY TEST; LETTER; PRIORITY JOURNAL; PROGNOSIS; SERUM; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MATRIX METALLOPROTEINASE 9; NEOPLASM CIRCULATING CELLS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 30444459227     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21405     Document Type: Letter

References (6)

1. Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinomas a prognostic marker. Int J Cancer 2005;7:7.
2. Jung K, Lein M, Laube C, Lichtinghagen R. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 2001;314:241-4.
3. Jung K, Laube C, Lein M, Lichtinghagen R, Tschesche H, Schnorr D, Loening SA. Kind of sample as pre-analytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin Chem 1998;44:1060-2.
4. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE. Effect of anticoagulants on plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 2005; 9 Jun [Epub ahead of print].
5. Makowski GS, Ramsby ML. Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma. Anal Biochem 2003;322:283-6.
6. Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos JE. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 2005;38:410-4.